Even if glcosepane's low tissue burden in rats means that cleaving it will not have dramatic rejuvenating effects in these animals (which is a
reasonable prediction, but might be happily disproven in the event), its high prevalence in
aging and diabetic human collagen, and its implication in the complications
of diabetes, will make the mere demonstration
of a candidate's ability to cleave glucosepane crosslinks in vivo a sufficient
proof -
of - concept to spur further work to move it down the therapeutic pipeline into human testing.